Schmidt CM - Search Results

1

Targeting MEK is effective chemoprevention of hepatocellular carcinoma in TGF-alpha-transgenic mice.

Wentz SC, Wu H, Yip-Schneider MT, Hennig M, Klein PJ, Sebolt-Leopold J, Schmidt CM. Wentz SC, et al. Among authors: schmidt cm. J Gastrointest Surg. 2008 Jan;12(1):30-7. doi: 10.1007/s11605-007-0396-4. Epub 2007 Nov 7. J Gastrointest Surg. 2008. PMID: 17987349

2

Inhibition of the phosphatidylinositol 3'-kinase signaling pathway increases the responsiveness of pancreatic carcinoma cells to sulindac.

Yip-Schneider MT, Wiesenauer CA, Schmidt CM. Yip-Schneider MT, et al. Among authors: schmidt cm. J Gastrointest Surg. 2003 Mar-Apr;7(3):354-63. doi: 10.1016/s1091-255x(02)00156-7. J Gastrointest Surg. 2003. PMID: 12654560

3

MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac.

Yip-Schneider MT, Schmidt CM. Yip-Schneider MT, et al. Among authors: schmidt cm. Pancreas. 2003 Nov;27(4):337-44. doi: 10.1097/00006676-200311000-00012. Pancreas. 2003. PMID: 14576498

4

Novel combination of cyclooxygenase-2 and MEK inhibitors in human hepatocellular carcinoma provides a synergistic increase in apoptosis.

Schmidt CM, Wang Y, Wiesenauer C. Schmidt CM, et al. J Gastrointest Surg. 2003 Dec;7(8):1024-33. doi: 10.1016/j.gassur.2003.09.009. J Gastrointest Surg. 2003. PMID: 14675712

5

Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma.

Wiesenauer CA, Yip-Schneider MT, Wang Y, Schmidt CM. Wiesenauer CA, et al. Among authors: schmidt cm. J Am Coll Surg. 2004 Mar;198(3):410-21. doi: 10.1016/j.jamcollsurg.2003.10.004. J Am Coll Surg. 2004. PMID: 14992744

6

Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells.

Yip-Schneider MT, Nakshatri H, Sweeney CJ, Marshall MS, Wiebke EA, Schmidt CM. Yip-Schneider MT, et al. Among authors: schmidt cm. Mol Cancer Ther. 2005 Apr;4(4):587-94. doi: 10.1158/1535-7163.MCT-04-0215. Mol Cancer Ther. 2005. PMID: 15827332

7

Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126.

Eppstein AC, Sandoval JA, Klein PJ, Woodruff HA, Grosfeld JL, Hickey RJ, Malkas LH, Schmidt CM. Eppstein AC, et al. Among authors: schmidt cm. J Pediatr Surg. 2006 Jan;41(1):252-9. doi: 10.1016/j.jpedsurg.2005.10.047. J Pediatr Surg. 2006. PMID: 16410143

8

The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer.

Klein PJ, Schmidt CM, Wiesenauer CA, Choi JN, Gage EA, Yip-Schneider MT, Wiebke EA, Wang Y, Omer C, Sebolt-Leopold JS. Klein PJ, et al. Among authors: schmidt cm. Neoplasia. 2006 Jan;8(1):1-8. doi: 10.1593/neo.05373. Neoplasia. 2006. PMID: 16533420 Free PMC article.

9

Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G0-G1 cell cycle arrest.

Ralstin MC, Gage EA, Yip-Schneider MT, Klein PJ, Wiebke EA, Schmidt CM. Ralstin MC, et al. Among authors: schmidt cm. Mol Cancer Res. 2006 Jun;4(6):387-99. doi: 10.1158/1541-7786.MCR-05-0157. Mol Cancer Res. 2006. PMID: 16778086 Free article.

10

Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia.

Crowell PL, Schmidt CM, Yip-Schneider MT, Savage JJ, Hertzler DA 2nd, Cummings WO. Crowell PL, et al. Among authors: schmidt cm. Neoplasia. 2006 Jun;8(6):437-45. doi: 10.1593/neo.04700. Neoplasia. 2006. PMID: 16820089 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

444 results

Search Page

Filters